Hosting News »

16 October, 2018 – 4:32 am |

“We made a decision to partner with GlobalSign, Europe’s longest serving Certificate Authority, as it offers the most trusted and inexpensive Code Signing and SSL security options now available in the digital certificate market,” Janmedia hosting director Alicja Baran related in an announcement. “GlobalSign’s digital certificates complement our existing product portfolio and we are anticipating […]

Read the full story »
Business News
energy
Aparatos
Environment
Science
Home » World News

Shares rise on stem cell study

Submitted by on 10 January, 2018 – 4:32 pm

Shares of Geron Corp. jumped Tuesday after the company said it began a clinical trial of embryonic stem cell treatment for injuries of the spinal cord.

SPARK: On Monday, the company said it received its first patient in phase 1 or early-stage study. The study aims to test the safety and tolerability not only the efficiency.

THE BIG PICTURE: Embryonic stem cells, which are derived from embryos, have the capacity to become any cell type. This study, which was expected, marks the first study approved by the Food and Drug Administration of an embryonic stem cell therapy.

ANALYSIS: Rodman & Renshaw analyst Reni Benjamin reaffirmed a “market outperform” rating and a price target of $ 9 in the population. He said the registration of a patient in the study “represents a landmark transformation of Geron.”

SOCIAL ACTION: up 33 cents, or 5.8 percent, to $ 6 in morning trading Tuesday. The stock has traded between $ 4.37 and $ 7.18 in the last 52 weeks.

Tags: , ,

Leave a comment!

Add your comment below, or trackback from your own site. You can also Comments Feed via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> 

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.